Sanofi (ADR) (NYSE:SNY)
CAPS Rating:
A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
The World's Greatest Investing Community
A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
UBS’s Amusa has a “sell” rating on Sanofi and has a “buy” rating on Novo Nordisk A/S, which produces a rival diabetes treatment called Levemir.
“We have to be careful not to taint a medicine which helps many patients, but if Sanofi have data we should see it,” said Kevin Scotcher, an analyst at Liberum Capital Ltd. in London. Sanofi’s Origin study, which is investigating the cardiovascular safety of Lantus, is likely to be completed in 2012, Bessaud said.